ARTICLES BY ERIN HARRIS
COVID-19 And Cell And Gene Sector: Contingency Planning For 2021 And Beyond
Some of the brightest luminaries representing the sector’s various subsets all answer the same question: As a result of COVID-19, how have you and your team had to pivot to ensure continued success in 2021 and beyond?
ARM’s Meeting on the Mesa 2020 — Disruptive Technologies that Will Change Cell Therapy
At ARM's Meeting on the Mesa 2020, I found the panel titled, Disruptive Technologies that Will Change the Cell Therapy Landscape, to be very informative. Here’s why.
Inside the Planning of Audentes’ Future Manufacturing Facility
Audentes’ Sanford, NC future facility, which will manufacture the company’s portfolio of adeno-associated virus-based gene therapies aimed at targeting serious rare neuromuscular diseases, is slated to be operational next year. Donald Wuchterl, Audentes’ Senior Vice President, Technical Operations talked to me about the best practices he and his team have implemented thus far in the planning stages, equipment needs, challenges and solutions, and more.
Driving Diversity And Inclusion In Life Sciences
Five experts weigh in on the status of diversity and inclusion in the life sciences industry and detail actions you can take now to drive awareness and change.
Cell & Gene And COVID-19
As the world rushes to combat the novel coronavirus behind the COVID-19 pandemic outbreak, the cell and gene sector has been impacted.
Challenges Facing The Cell And Gene Sector’s Regulation Landscape
Here are the critical action items cell and gene therapy professionals should heed to keep pace with the sector’s ever-evolving regulations.
Potential Solutions To Current Pricing Models For Cell And Gene Therapies
Curative cell & gene therapies are changing modern medicine as we know it, but are their high price tags fair to the patient?
Tackling Cell & Gene Therapy Financing & Manufacturing Challenges
As interest in the cell and gene market continues to heat up, the sector’s manufacturing and finance challenges have become top priorities.
The Unique Demands of Cell and Gene Therapy Supply Chains
Three cell and gene therapy sector SMEs representing industry and academia explain supply chain challenges and viable solutions.